Exclusive development and commercialization rights to VIR-3434 in China strengthen Company's leader...
Data are consistent with the results of the global Phase 3 ACTIV-2 trial, demonstrating a favorable...
DURHAM, N.C. and BEIJING, May 25, 2022 /PRNewswire/ -- Brii Biosciences Limited
2022-05-25 08:00
6531
* Studies conducted by independent labs demonstrate the amubarvimab/romlusevimab combination reta...
DURHAM, N.C. and BEIJING, May 7, 2022 /PRNewswire/ -- Brii Biosciences Limited
2022-05-07 09:00
6802
New data demonstrate BRII-835 (VIR-2218) was well tolerated with notable reductions in serum HBsAgo...
DURHAM, N.C. and BEIJING, March 30, 2022 /PRNewswire/ -- Brii Biosciences
Limited
2022-03-30 08:05
4378
– Advancing key programs in HBV, CNS, and HIV – – Received first BLA approval for COVID-19 Treatme...
The amubarvimab/romlusevimab combination is the first locally-discovered and approved SARS-CoV-2 ta...
DURHAM, N.C. and BEIJING, Jan. 27, 2022 /PRNewswire/ -- Brii Biosciences
2022-01-27 21:00
5763
DURHAM, N.C. and BEIJING, Dec. 27, 2021 /PRNewswire/ -- Brii Biosciences
2021-12-27 18:45
4765
DURHAM, N.C. and BEIJING, Dec. 12, 2021 /PRNewswire/ -- Brii Biosciences
2021-12-12 18:50
5265
The approval marks the first locally-discovered and approved SARS-CoV-2 target-specific treatment i...
DURHAM, N.C. and BEIJING, Dec. 6, 2021 /PRNewswire/ -- Brii Biosciences
2021-12-06 10:54
5164
DURHAM, N.C. and BEIJING, Nov. 19, 2021 /PRNewswire/ -- Brii Biosciences
2021-11-19 19:06
4688
BEIJING and DURHAM, N.C., Nov. 17, 2021 /PRNewswire/ -- Brii Biosciences Limited
2021-11-17 18:52
5099
DURHAM, N.C. and BEIJING, Oct. 9, 2021 /PRNewswire/ -- Brii Biosciences
2021-10-09 03:07
6557
DURHAM, N.C.and BEIJING, Oct. 4, 2021 /PRNewswire/ -- Brii Biosciences
2021-10-04 08:00
4776
DURHAM, N.C. and BEIJING, Sept. 28, 2021 /PRNewswire/ -- Brii Biosciences
2021-09-28 08:00
6170